PROFUND ADVISORS LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.

Quarter-by-quarter ownership
PROFUND ADVISORS LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$828,377
-39.6%
40,154
-13.6%
0.05%
-37.8%
Q2 2023$1,371,477
+21.9%
46,475
-4.8%
0.07%
+5.7%
Q1 2023$1,124,974
+172.1%
48,827
+228.4%
0.07%
+159.3%
Q4 2022$413,451
+3.9%
14,867
+14.7%
0.03%
-6.9%
Q3 2022$398,000
+5.9%
12,962
+1.5%
0.03%
+20.8%
Q2 2022$376,000
-18.1%
12,776
-10.4%
0.02%
+26.3%
Q1 2022$459,000
-35.0%
14,254
-10.0%
0.02%
-17.4%
Q4 2021$706,000
-20.8%
15,840
-10.3%
0.02%
-23.3%
Q3 2021$891,000
+324.3%
17,653
+560.9%
0.03%
+328.6%
Q2 2021$210,0002,6710.01%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders